Can I Take Creatine with Rapamycin (Sirolimus)?

Sirolimus (brand name Rapamune) is an mTOR inhibitor approved by the FDA in 1999 to prevent rejection in kidney transplant recipients. It is also used off-label, typically at low intermittent doses, by clinicians running longevity or aging-focused protocols. Creatine monohydrate is an over-the-counter supplement used for muscle performance and lean mass.

There is no known pharmacokinetic interaction between creatine and sirolimus. Creatine does not affect CYP3A4 or P-glycoprotein, the two pathways that govern sirolimus absorption and clearance, and creatine does not appear among the interactions listed in the FDA-approved Rapamune label. The genuine issue is a measurement problem, not a drug interaction: creatine supplementation is well established in the sports-medicine literature to raise serum creatinine as a normal byproduct of muscle phosphocreatine turnover, and this can look like worsening kidney function in a patient whose sirolimus regimen is being monitored partly through creatinine trends. That distinction, and how to manage it, is what this page addresses.

What is established, what is plausible, and what is not proven

Established. Sirolimus is cleared almost entirely through hepatic CYP3A4 and is a P-glycoprotein substrate. The FDA label lists interacting agents that change sirolimus blood levels through these pathways, including ketoconazole, rifampin, cyclosporine, diltiazem, verapamil, and grapefruit juice. Creatine is not one of them. Separately, creatine supplementation raising serum creatinine is a long-recognized phenomenon in sports medicine and nephrology literature, driven by increased muscle creatine turnover rather than reduced kidney filtration.

Plausible but unproven in this combination. Sirolimus suppresses mTORC1-driven muscle protein synthesis, and at least one human trial has reported a substantial reduction in the anabolic response to resistance exercise after rapamycin dosing. Creatine's muscle benefits work partly through pathways other than mTORC1 activation, including phosphocreatine resynthesis and satellite cell signaling. It is mechanistically reasonable that creatine could partially offset some of sirolimus's anabolic blunting, but no published trial has tested creatine supplementation specifically in people taking sirolimus, so this remains an inference from separate bodies of evidence rather than a demonstrated effect.

Not established. The exact magnitude of creatinine rise a given patient will see on a specific creatine dose while also taking sirolimus has not been studied directly. Figures circulating for creatine-related creatinine increases come from studies in people not taking mTOR inhibitors, and the precise numbers vary across studies and doses. Anyone relying on a specific mg/dL threshold to interpret a real patient's labs should verify the current primary literature rather than treat any single number as authoritative.

The compact version: creatine and sirolimus do not interact pharmacologically, creatine can raise creatinine independent of true kidney function, and cystatin C testing (a filtration marker not affected by muscle creatine turnover) is the practical way to tell an artifact from a real problem. Everything else on this page builds on those three points.

Why sirolimus monitoring is creatinine-sensitive to begin with

Sirolimus carries a real nephrotoxicity signal, particularly when combined with calcineurin inhibitors such as tacrolimus or cyclosporine in transplant regimens. Even when used alone in off-label longevity protocols, prescribing clinicians typically order a metabolic panel at baseline and again a few weeks after starting or changing therapy, then periodically thereafter, because creatinine is one of the more accessible ways to track kidney trend over time.

That monitoring habit is exactly what creates the ambiguity with creatine. Serum creatinine is generated from the breakdown of phosphocreatine in muscle. Add exogenous creatine, and total body phosphocreatine stores expand, so daily creatinine production rises somewhat, independent of anything happening at the glomerulus. In a healthy person with no other reason to be tracked closely, this is a non-issue. In someone whose transplant team or longevity physician is trending creatinine as a rejection or nephrotoxicity signal, an unexplained rise can trigger unnecessary concern, dose changes, or workup.

Loading versus maintenance dosing

Creatine is sometimes loaded at higher doses (commonly cited around 20 g/day split across the day) for the first several days, then continued at a lower maintenance dose (commonly 3 to 5 g/day). Loading protocols produce a sharper, more variable rise in serum creatinine than maintenance dosing does. Long-term outcome data does not show that loading produces better strength or lean mass results than starting at a maintenance dose directly, so for anyone on sirolimus, skipping the loading phase and starting at a maintenance dose is the more conservative and equally effective choice. Exact numeric expectations for the creatinine rise at either dose should be confirmed against current primary literature rather than assumed from any single cited figure, since reported magnitudes vary by study population and hydration status.

Cystatin C as the tiebreaker

Cystatin C is filtered at the glomerulus and metabolized by tubular cells; unlike creatinine, its production is not driven by muscle mass or dietary creatine intake. Nephrology literature on GFR estimation generally treats cystatin C as a useful cross-check in situations where creatinine is being distorted by diet or muscle mass rather than by true kidney function. For a patient on sirolimus who wants to start creatine, a baseline cystatin C measurement, repeated alongside creatinine after starting the supplement, gives the clearest read: if creatinine rises but cystatin C stays flat, the change is most consistent with a supplement-related artifact rather than a kidney event. If both rise together, that pattern deserves closer clinical attention and should be reviewed with the prescribing physician promptly.

The muscle biology: where sirolimus and creatine actually meet

MTORC1 signaling drives ribosomal translation of new muscle protein following resistance exercise, and rapamycin-class drugs blunt that signal. A published human trial reported a substantial reduction in exercise-induced muscle protein synthesis after rapamycin dosing, though the exact percentage reported in that study should be confirmed against the original paper before being treated as a fixed number for patient counseling.

Creatine's muscle effects run through several mechanisms, not solely mTORC1 activation: faster ATP regeneration during high-intensity effort, increased phosphocreatine stores, and satellite cell and glycogen-related effects that operate at least partly independent of mTOR signaling. Meta-analytic work in sports science has consistently found creatine supplementation improves lean mass and strength outcomes across varied populations, though this evidence base was generated in people not taking mTOR inhibitors.

Evidence-status interaction assessment: creatine plus sirolimus

Practical guidance for the two main groups of sirolimus users

Kidney transplant recipients

Transplant teams track creatinine closely, sometimes monthly, because it functions as an early signal of graft dysfunction. An unexplained rise can trigger further workup, including biopsy in some cases. For this population, starting creatine without informing the transplant nephrologist risks a diagnostic detour that has nothing to do with actual graft health. This is a disclosure issue, not necessarily a contraindication: discuss the plan, establish a cystatin C baseline if possible, and let the transplant team decide on the monitoring adjustment. Do not start creatine on your own initiative if you are a transplant recipient without this conversation happening first.

Off-label longevity users

Adults using low-dose intermittent sirolimus under a longevity protocol generally have normal baseline kidney function and less intensive monitoring than transplant patients. For this group, creatine at a maintenance dose, paired with a baseline and follow-up cystatin C check, is a reasonable and mechanistically supported choice, though still one without direct trial evidence in sirolimus users specifically. It should still be disclosed to the prescribing clinician so the monitoring plan accounts for it.

A monitoring conversation to have before starting creatine

• Confirm baseline serum creatinine, BUN, and eGFR, and add a cystatin C level if available, especially if baseline eGFR is reduced.
• Record the current sirolimus dosing schedule and, if applicable, trough level, so any future lab change can be interpreted against a known reference point.
• Agree with the prescribing clinician on a recheck timeline (commonly several weeks after starting creatine) rather than waiting for the next routine visit.
• Ask specifically: if creatinine rises but cystatin C does not, will the plan be to continue creatine, or to pause and reassess?
• Ask what threshold of creatinine change, or any new proteinuria, should prompt an unscheduled visit rather than waiting for the next scheduled panel.

Other supplements that actually do interact with sirolimus

Unlike creatine, several supplements have recognized pharmacokinetic interactions with sirolimus through CYP3A4 or P-glycoprotein. St. John's Wort induces CYP3A4 and can lower sirolimus levels enough to risk under-immunosuppression. Grapefruit products and certain other CYP3A4 inhibitors can raise sirolimus levels. Any new supplement, not just creatine, should be reviewed against the current Rapamune label and with the prescribing physician, since sirolimus is one of the more interaction-sensitive immunosuppressants in routine use.

When to seek urgent care

New or worsening swelling, a marked and unexplained rise in creatinine, new protein in the urine, reduced urine output, or any symptoms of infection in a transplant patient warrant prompt contact with the transplant team rather than waiting for a routine appointment. These are signals that should be evaluated regardless of whether creatine is part of the picture.

Evidence quality, honestly stated

Creatine's effect on serum creatinine is a well-established phenomenon in the broader sports medicine and nephrology literature, though the exact numeric magnitude reported varies by study and should be verified before being used in patient counseling. Sirolimus's nephrotoxicity risk, particularly in combination with calcineurin inhibitors, is well documented in transplant medicine. The absence of a pharmacokinetic interaction between creatine and sirolimus is supported by mechanism and is consistent with the FDA label's list of interacting agents, which does not include creatine. The idea that creatine could offset some of sirolimus's suppression of muscle protein synthesis is mechanistically plausible but has not been tested in a trial that combines the two agents in the same subjects. This page's overall judgment is that the combination is likely manageable with monitoring, not proven safe by direct trial evidence.